Ocular Therapeutix (OCUL) Net Margin (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Net Margin of 589.63% for Q2 2026, down 9032.0% year-over-year from 6.6% in Q2 2025, and up 29.4% on a QoQ basis from 835.11% in Q1 2026.
Powered by 
Analysis
Ocular Therapeutix (OCUL) Net Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Net Margin for 13 years, with the latest figure at 589.63% in Q2 2026.
- Net Margin for Q2 2026 came in at 589.63%, down 9032.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 581.59% (down 18829.0% YoY), and the FY2025 annual result was 1047.35%, down 45613.0% from the prior year.
- Net Margin grew to 589.63% in Q2 2026, from 835.11% in the prior quarter.
- Over five years, Net Margin peaked at 113.97% in Q4 2023 and troughed at 835.11% in Q1 2026.
- A 5-year average of 321.65% and a median of 261.54% in 2024 frame the typical range for Net Margin.
- The widest annual swing landed in 2022, when Net Margin surged 15036 bps; it then tumbled 31437 bps in 2025.
- A 5-year view of Net Margin shows it stood at 130.43% in 2022, then increased by 13 bps to 113.97% in 2023, then sank by 152 bps to 286.92% in 2024, then plunged by 72 bps to 492.45% in 2025, then decreased by 20 bps to 589.63% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 589.63% in Q2 2026, 835.11% in Q1 2026, and 492.45% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Ocular Therapeutix | 2.40 Bn | 2.40 Bn | 11.46 Mn | -589.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -589.63% |
| Mar 31, 2026 | -835.11% |
| Dec 31, 2025 | -492.45% |
| Sep 30, 2025 | -467.35% |
| Jun 30, 2025 | -499.31% |
| Mar 31, 2025 | -589.60% |
| Dec 31, 2024 | -286.92% |
| Sep 30, 2024 | -282.46% |
| Jun 30, 2024 | -247.86% |
| Mar 31, 2024 | -214.88% |
| Dec 31, 2023 | -153.65% |
| Sep 30, 2023 | -142.09% |
| Jun 30, 2023 | -143.64% |
| Mar 31, 2023 | -177.61% |
| Dec 31, 2022 | -147.67% |
| Sep 30, 2022 | -192.70% |
| Jun 30, 2022 | -175.60% |
| Mar 31, 2022 | -147.86% |
| Dec 31, 2021 | -160.25% |
| Sep 30, 2021 | -174.28% |